-
21
Supplementary Table S1 from Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women
Gepubliceerd in 2025Onderwerpen: -
22
Table S2 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
23
Table S3 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
24
Table S4 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
25
Table S7 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
26
Table S1 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
27
Table S6 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
28
Table S5 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
Gepubliceerd in 2025Onderwerpen: -
29
-
30
Multivariate analysis between DENV and CHIKV seroconversion and selected risk factors.
Gepubliceerd in 2025Onderwerpen: -
31
Seroprevalence of DENV and CHIKV among study participants in Kisumu and Ukunda, Kenya, Dec 2019 – Feb 2022.
Gepubliceerd in 2025Onderwerpen: -
32
Descriptive statistics and demographics of study participants, Ukunda and Kisumu sites, Kenya, Dec 2019–Feb 2022.
Gepubliceerd in 2025Onderwerpen: -
33
-
34
Univariate analysis between DENV and CHIKV seropositivity and selected risk factors.
Gepubliceerd in 2025Onderwerpen: -
35
Seroconversion of DENV and CHIKV among study participants in Kisumu and Ukunda, Kenya, Dec 2019 – Feb 2022.
Gepubliceerd in 2025Onderwerpen: -
36
Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.
Gepubliceerd in 2025Onderwerpen: -
37
Kaplan Meier survival curves for new DENV seropositivity during the 2-year study period from Dec 2019 – Feb 2022..
Gepubliceerd in 2025Onderwerpen: -
38
Multivariate analysis between DENV and CHIKV seropositivity and selected risk factors.
Gepubliceerd in 2025Onderwerpen: -
39
Univariate analysis between DENV and CHIKV seroconversion and selected risk factors.
Gepubliceerd in 2025Onderwerpen: -
40
Distribution of DENV and CHIKV seroprevalence by age group of participants in the study.
Gepubliceerd in 2025Onderwerpen: